Low Back Pain Treatment in Birmingham & Bessemer, AL

Back Pain Treatment at Alabama Pain Physicians

Low back pain is the most common reason patients come to our practice. Our board-certified physicians have been treating back pain in Birmingham and Bessemer since 2009 — and we use every tool available to get you better.

Your treatment plan may include:

• Medical management — medications including opioid therapy when appropriate, nerve stabilizers, anti-inflammatories, and muscle relaxants tailored to your specific pain
• Epidural steroid injections — targeted injections to reduce inflammation around compressed nerves
• Facet joint injections and medial branch blocks — diagnosing and treating pain from the small joints of the spine
• Radiofrequency ablation (RF) — using heat to interrupt pain signals from specific nerves, providing months of relief
• Spinal cord stimulation (SCS) — implantable technology for chronic pain that hasn't responded to other treatments
• SI joint injections — addressing sacroiliac joint dysfunction, a common but often missed source of low back pain
• Kyphoplasty — minimally invasive treatment for vertebral compression fractures
• Medical marijuana certification — for qualifying patients who may benefit from medical cannabis

Every patient is different. We start with a thorough evaluation, review your imaging and history, and build a treatment plan specific to your situation. Most major insurance is accepted.

Understanding Back Pain: A Multi-System Perspective

The following publication by Ty Thomas, MD explores the deeper biological mechanisms behind why back pain develops and persists. This research informs how we approach complex and treatment-resistant cases at Alabama Pain Physicians.

Author’s Statement

I am a board-certified Physical Medicine and Rehabilitation physician with additional certification in Venous and Lymphatic Medicine. For over fifteen years at Alabama Pain Physicians, I have managed thousands of patients with chronic pain conditions including low back pain, radiculopathy, neuropathy, and fibromyalgia. The consistent observation that drives this publication series is the limited, partial treatment response that characterizes chronic pain management across conventional modalities. Epidural steroid injections provide relief for weeks or months, then the pain returns. Opioids modulate perception without addressing pathology. Surgical correction of a structural lesion succeeds in some patients and fails in others with identical imaging findings. These partial responses are not clinical failures in the traditional sense — each intervention does what it is designed to do. They are evidence that the interventions are addressing only one component of a multi-component problem. This observation led me to cellular systems biology and theory as a framework for understanding the clinical entities I encounter daily. The concept that chronic pain emerges from dynamic interactions across metabolic, inflammatory, hormonal, microbiome, mitochondrial, vascular, and structural domains — rather than from isolated structural pathology — makes clinical sense and has improved outcomes in my practice. I have spent years developing assessment protocols, building laboratory infrastructure through CLIA-certified laboratories, and studying the biological pathways that connect these domains. I own clinics, laboratories, and value-based care companies with the goal of providing patients better outcomes. Better outcomes require questioning our current understanding and applying different conceptual frameworks to better explain pathology and wellness. I believe the cellular systems approach provides a more complete lens for understanding chronic low back pain and for directing treatment toward the biological environment in which structural damage occurs and persists. These publications are my attempt to provide information about this understanding — how common clinical manifestations of pain can be explained, diagnosed, and treated through cellular systems analysis. They are not a claim to have found a root cause. They are a framework for asking better questions.

Abstract

Background

Low back pain is the leading cause of disability worldwide, affecting an estimated 619 million people in 2020 with projections to 843 million by 2050 (GBD 2021, Lancet Rheumatology, 2023). Current treatment approaches target individual mechanisms: NSAIDs inhibit cyclooxygenase-mediated inflammation, opioids modulate mu-receptor pain perception, epidural steroid injections suppress perineural inflammation, and surgery corrects structural compression. A 2025 systematic review of 301 trials examining 56 treatments found that only 1 in 10 non-surgical, non-interventional treatments for low back pain are efficacious, with effect sizes that were uniformly small (Cashin et al., BMJ Evidence Based Medicine, 2025). Opioids for chronic low back pain have an NNT of 19 for 50% pain reduction (Petzke et al., Schmerz, 2015). Epidural steroid injections show strong short-term but insufficient evidence for long-term pain reduction (AAN Guidelines, Neurology, 2025). These limited response rates suggest that single-pathway interventions are insufficient for a condition involving multiple biological systems.

Methods

We conducted a narrative review of PubMed-indexed literature examining low back pain through cellular systems theory, which proposes that chronic low back pain emerges from dynamic interactions across seven biological domains. We reviewed evidence for metabolic, mitochondrial, inflammatory, neuroendocrine, microbiome, vascular, and structural domain involvement in spinal degeneration and chronic pain, analyzed treatment response data for conventional interventions, and constructed composite clinical scenarios illustrating individualized multi-domain assessment and intervention including emerging peptide therapeutics.

Results

Published evidence demonstrates that low back pain involves dysfunction across multiple biological domains: insulin resistance is independently associated with increased risk of low back pain in a cross- sectional study of 6,126 adults (Que et al., Frontiers in Medicine, 2025); Mendelian randomization indicates metabolic factors may affect disc degeneration more than mechanical factors (Guo et al., Spine Journal, 2024); metabolic syndrome components are associated with disc degeneration across the entire spine (Teraguchi et al., PLoS One, 2016); chronic pain and insulin resistance have a bidirectional relationship in which nerve injury accelerates metabolic dysfunction (Zhai et al., Journal of Pain, 2016); 37% of asymptomatic 20-year-olds and 96% of asymptomatic 80-year-olds have disc degeneration on imaging (Brinjikji et al., AJNR, 2015), indicating that structural pathology alone is insufficient to explain symptoms. Inflammatory mediators including TNF-α are required for nerve root compression to produce symptoms (Olmarker et al., Spine, 1993). Sleep disruption independently predicts chronic pain development (Finan et al., Journal of Pain, 2013). Altered gut microbiome composition correlates with pain severity (Minerbi et al., Pain, 2019).

Conclusions

The pattern of multi-domain biological dysfunction combined with limited, partial response to single-pathway treatments supports the hypothesis that chronic low back pain represents a multi-system cellular disorder requiring individualized, domain-specific intervention. Cellular systems theory provides a framework for identifying which domains are dysfunctional in each patient and directing treatment accordingly. Emerging peptide therapeutics targeting metabolic, mitochondrial, inflammatory, and tissue repair pathways offer potential for domain- targeted intervention, though clinical evidence remains largely preclinical.

1. Introduction

Low back pain is the leading cause of disability worldwide. The Global Burden of Disease Study 2021 estimated that 619 million people experienced low back pain in 2020, with projections reaching 843 million by 2050 driven by population growth and aging (GBD 2021, Lancet Rheumatology, 2023). In the United States, direct medical costs for low back and neck pain combined exceed $134.5 billion annually (Dieleman et al., JAMA, 2020). Low back pain is the most common reason for years lived with disability across all age groups in both developed and developing nations (Hartvigsen et al., Lancet, 2018). The prevailing clinical model for low back pain is structural-mechanical. A patient presents with pain. Imaging reveals a disc herniation, facet arthropathy, or spinal stenosis. Treatment targets the structural finding: an epidural injection to reduce inflammation around the disc, a nerve block to quiet the facet joint, or surgery to decompress the stenotic segment. This model is logical, evidence-based for acute intervention, and frequently effective in the short term. However, the long-term clinical performance of structural-mechanical interventions challenges the sufficiency of this model. A meta-analysis of 29 randomized controlled trials found that the long-term benefit (≥6 months) of epidural steroid injections for low back pain was not supported after baseline adjustment, and epidural steroid injection did not reduce the number of patients who underwent subsequent surgery compared with placebo (Bicket et al., Anesthesiology, 2013). Opioids for chronic low back pain showed an NNT of 19 for 50% pain reduction in a systematic review and meta-analysis of 12 RCTs with 4,375 participants, meaning approximately 19 patients must be treated for one to achieve meaningful pain relief beyond placebo (Petzke et al., Schmerz, 2015). Long-term opioid efficacy beyond 16 weeks remains unclear (Martell et al., Annals of Internal Medicine, 2007). A 2025 systematic review of 301 placebo-controlled trials examining 56 non-surgical treatments found that only 1 in 10 are efficacious for low back pain, with uniformly small effect sizes (Cashin et al., BMJ Evidence Based Medicine, 2025). Antidepressants showed no difference from placebo for chronic non-specific low back pain (Kuijpers et al., European Spine Journal, 2011). Most critically, disc degeneration on imaging — the structural finding that typically drives treatment decisions — is nearly universal in the asymptomatic population. A systematic review found that disc degeneration was present in 37% of asymptomatic 20-year-olds and 96% of asymptomatic 80-year-olds (Brinjikji et al., AJNR, 2015). Two patients with identical disc herniations at L4-5 can present with dramatically different clinical pictures — one recovering spontaneously, the other progressing to chronic disability. The structural finding is the same. Something else determines the clinical outcome. Cellular systems theory proposes that the “something else” is the biological environment in which the structural damage exists. The disc does not degenerate in isolation. It degenerates within a metabolic, inflammatory, hormonal, vascular, and immunological context that either supports or undermines its integrity and repair. When that biological environment is dysfunctional across multiple domains simultaneously, structural interventions alone cannot produce sustained improvement because the biological conditions that caused the structural damage — and that prevent its repair — remain active.

2. Methods

We conducted a narrative review of PubMed-indexed literature examining biological domain dysfunction in chronic low back pain. Search terms included low back pain combined with insulin resistance, metabolic syndrome, disc degeneration, inflammation, NF-κB, cytokines, HPA axis, cortisol, microbiome, intestinal permeability, oxidative stress, mitochondrial dysfunction, endothelial dysfunction, microvascular, and treatment response. We included systematic reviews, meta-analyses, randomized controlled trials, Mendelian randomization studies, and large population- based cohort studies published in English-language peer-reviewed journals. We analyzed treatment response data from systematic reviews and meta- analyses of conventional low back pain interventions. We constructed composite clinical scenarios to illustrate individualized multi-domain assessment and intervention.

3. The Limitations of Single-Pathway Treatment

Current low back pain treatments each target a single biological mechanism. Their collective treatment effect data reveal a consistent pattern of limited, short-term, partial efficacy.

3.1 Pharmacological Interventions

NSAIDs inhibit cyclooxygenase enzymes, reducing prostaglandin-mediated inflammation. They are the only pharmacological agent with moderate- certainty evidence of efficacy for acute low back pain (Cashin et al., BMJ Evidence Based Medicine, 2025), but evidence for chronic low back pain shows only short-term, small effects with more adverse events than placebo (Kuijpers et al., European Spine Journal, 2011). NSAIDs do not address the metabolic, hormonal, microbiome, or mitochondrial domains. Opioids modulate mu-receptor pain perception. A systematic review of 12 RCTs with 4,375 participants found an NNT of 19 for 50% pain reduction in chronic low back pain (Petzke et al., Schmerz, 2015). Opioids were not superior to placebo for reports of “much or very much improved” pain. Long-term efficacy beyond 16 weeks is unclear, and aberrant medication- taking behaviors occur in up to 24% of patients (Martell et al., Annals of Internal Medicine, 2007). Opioids suppress the HPA axis, reduce testosterone, disrupt sleep architecture, promote constipation (worsening gut function), and cause weight gain — actively worsening multiple biological domains while modulating pain perception in one. Antidepressants showed no difference from placebo for chronic non-specific low back pain in a systematic review using the GRADE evidence approach (Kuijpers et al., European Spine Journal, 2011). Muscle relaxants found no studies meeting inclusion criteria for chronic LBP in the same review.

3.2 Interventional Procedures

Epidural steroid injections reduce perineural inflammation at a specific spinal segment. The 2025 AAN systematic review of 90 RCTs found that ESIs probably reduce short-term pain in radiculopathy (NNT 4, success rate difference 24%) but found insufficient evidence for long-term pain reduction (AAN Guidelines, Neurology, 2025). A meta-analysis of 29 RCTs found that long-term benefit was not supported after baseline adjustment, and ESIs did not reduce subsequent surgery rates (Bicket et al., Anesthesiology, 2013). ESIs target local inflammation at one level of the spine. They do not address the systemic metabolic and inflammatory environment that produced the disc degeneration, nor do they influence the vascular supply to the disc, the hormonal environment governing tissue repair, or the sleep disruption preventing recovery. Lumbar fusion surgery for degenerative disc disease produces inconsistent outcomes. The Lancet series on low back pain noted that surgery should be considered only when conservative management has failed, and that even appropriately indicated surgery does not address the biological environment that produced the degeneration (Foster et al., Lancet, 2018). Patients with successful structural decompression who continue to have unaddressed metabolic dysfunction, systemic inflammation, hormonal insufficiency, and sleep disruption frequently develop adjacent segment degeneration or persistent pain at the treated level — not because the surgery failed, but because the biology that damaged the first segment remains active.

3.3 Synthesis: The Pattern of Partial Response

The treatment response data across all conventional modalities converge on a consistent pattern: each intervention provides limited, often short-term benefit to a minority of patients. One in 10 non-surgical treatments is efficacious, with small effect sizes (Cashin et al., 2025). Opioid NNT is 19 for chronic LBP (Petzke et al., 2015). ESIs show short-term but not long- term benefit (AAN, 2025; Bicket et al., 2013). Antidepressants show no benefit over placebo (Kuijpers et al., 2011). This is the pattern predicted by a multi-domain disorder being treated with single-domain interventions. If chronic low back pain involves variable dysfunction across metabolic, inflammatory, hormonal, microbiome, mitochondrial, vascular, and structural domains, and each patient’s pain reflects a unique combination of domain dysfunction, then a single- mechanism agent would be expected to help only the subset of patients in whom that mechanism is the dominant driver. The limited response rates and the bimodal distribution of outcomes are not evidence that the interventions are ineffective — they are evidence that the interventions are incomplete.

4. Evidence for Multi-Domain Dysfunction in Low Back Pain

4.1 Mitochondrial Function and Metabolic Dysfunction

Insulin resistance is independently associated with increased risk of low back pain. Que et al. analyzed data from 6,126 US adults in the National Health and Nutrition Examination Survey and found that multiple insulin resistance measures (HOMA-IR, triglyceride-glucose index, TyG-BMI, TyG- waist circumference) were independently associated with increased risk of low back pain in cross-sectional analysis (Que et al., Frontiers in Medicine, 2025). A Mendelian randomization study found that genetically predicted metabolic factors including triglycerides may affect intervertebral disc degeneration more than mechanical factors, establishing a potential causal pathway from metabolic dysfunction to structural damage (Guo et al., Spine Journal, 2024). The Wakayama Spine Study, a large population-based cohort, found that metabolic syndrome components are significantly associated with disc degeneration across the cervical, thoracic, and lumbar spine (Teraguchi et al., PLoS One, 2016). The mechanisms connecting insulin resistance to disc degeneration operate through multiple pathways. Chronically elevated blood sugar produces advanced glycation end products (AGEs) — compounds that cross-link collagen fibers, stiffening the disc matrix and impairing nutrient diffusion. Insulin resistance promotes NF-κB activation, upregulating matrix metalloproteinases (MMPs) — enzymes that degrade the collagen and proteoglycan matrix of the disc (Risbud and Shapiro, Nature Reviews Rheumatology, 2014). Visceral adipose tissue produces inflammatory cytokines including TNF-α and IL-6 that enter systemic circulation and reach the disc through its limited vascular supply. The relationship between pain and insulin resistance is bidirectional: animal models demonstrate that chronic pain downregulates insulin receptors in skeletal muscle and spinal cord, accelerating progression to metabolic dysfunction (Zhai et al., Journal of Pain, 2016).

4.2 Immune Surveillance and Inflammation

Inflammatory mediators are required for nerve root compression to produce radicular symptoms. Olmarker et al. demonstrated in animal models that application of nucleus pulposus material to a nerve root without mechanical compression produces inflammatory changes and pain behavior, while compression without inflammatory mediators produces significantly less nociceptive response (Olmarker et al., Spine, 1993). This finding has profound implications: it means that the inflammatory environment surrounding the nerve root determines whether a given degree of structural compression becomes symptomatic. Cytokines produced within the degenerating disc itself activate the NF-κB inflammatory signaling pathway — a protein complex that functions as a master switch for inflammatory gene activation, driving production of matrix-degrading enzymes and inflammatory mediators that accelerate disc breakdown (Risbud and Shapiro, Nature Reviews Rheumatology, 2014; Niederberger and Geisslinger, FASEB Journal, 2008). Immune cells including activated microglia and astrocytes in the spinal cord dorsal horn contribute to central sensitization — a state of neural hyperexcitability that amplifies pain signals and lowers pain thresholds — by releasing proinflammatory cytokines that enhance synaptic transmission in pain pathways (Watkins and Maier, Physiological Reviews, 2002; Woolf, Pain, 2011).

4.3 Neuroendocrine Regulation

Sleep disruption independently predicts the transition from acute to chronic pain and the development of widespread pain conditions (Finan et al., Journal of Pain, 2013). Poor sleep quality is bidirectionally linked to pain: sleep disruption amplifies pain, and pain disrupts sleep, creating a self- reinforcing cycle (Choy, Nature Reviews Rheumatology, 2015). Growth hormone, released primarily during deep (delta) sleep, is essential for collagen synthesis, proteoglycan production, and tissue repair in the disc and surrounding structures. Chronic sleep disruption reduces growth hormone release, impairing the body’s primary repair window. HPA axis dysregulation — the body’s central stress response system — affects connective tissue integrity directly. Sustained cortisol elevation from chronic stress degrades collagen, weakens connective tissue, and promotes inflammatory disinhibition (Heim et al., Psychoneuroendocrinology, 2000). Hormonal insufficiency, including testosterone deficiency in both men and women, reduces the anabolic capacity needed for tissue repair and maintenance.

4.4 Microbiome and Mucosal Immunity

Gut barrier dysfunction allows bacterial lipopolysaccharide (LPS) to translocate into systemic circulation, activating NF-κB-mediated inflammatory cascades (Camilleri, Gut, 2019). This gut-derived systemic inflammation contributes to the same inflammatory tone that sensitizes nerve roots and promotes disc degeneration. Altered gut microbiome composition has been demonstrated in chronic pain populations, with specific bacterial taxa correlating with pain severity (Minerbi et al., Pain, 2019). Small intestinal bacterial overgrowth (SIBO) has been associated with chronic pain syndromes (Erdrich et al., Clinical and Experimental Rheumatology, 2020). Gut dysbiosis alters tryptophan metabolism, reducing serotonin availability and weakening descending pain inhibition.

4.5 Detoxification and Oxidative Stress

Oxidative stress is recognized as a key pathogenic factor in intervertebral disc degeneration (Li et al., Oxidative Medicine and Cellular Longevity, 2022; Wang et al., Cell Proliferation, 2023). Reactive oxygen species damage disc cells through multiple pathways: ROS activate NF-κB and MAPK signaling pathways, upregulating MMPs and catabolic factors including COX-2 and TNF-α while suppressing aggrecan production (Suzuki et al., Spine, 2015). Advanced glycation end products accumulate in disc tissue and trigger NLRP3 inflammasome activation through the RAGE/NF-κB pathway, linking oxidative stress directly to the metabolic domain (PMC, 2022). Patients with more severe disc degeneration (Pfirrmann grades IV and V) have higher lipid peroxidation levels than those with less severe degeneration, directly correlating oxidative damage with disease severity (PMC, 2024). The Nrf2 antioxidant defense system — the master regulator of antioxidant gene expression including glutathione, superoxide dismutase, and catalase — is increasingly recognized as a therapeutic target in disc degeneration (Experimental and Molecular Medicine, 2022). When glutathione and other antioxidant defenses are depleted by chronic metabolic stress, disc cells lose protection against oxidative damage while the clearance of inflammatory prostaglandins and leukotrienes is impaired. Environmental toxic burden including heavy metals may contribute to systemic inflammatory tone, though the evidence base for direct disc-specific toxicity requires further investigation.

4.6 Vascular Integrity

The intervertebral disc depends on diffusion from capillaries at its margins for nutrient delivery and waste removal. The nucleus pulposus is avascular throughout life, and disc cells obtain glucose and oxygen primarily through capillary beds that penetrate the vertebral endplate (Urban et al., Spine, 2004; PMC, 2018). Loss of this nutrient supply leads to cell death, reduced matrix production, and increased matrix degradation — and hence to disc degeneration (Urban et al., Spine, 2004). Critically, Kauppila demonstrated in a systematic review that atherosclerosis of the abdominal aorta and stenosis of the lumbar arterial orifices are associated with disc degeneration and low back pain, establishing a direct link between systemic vascular disease and spinal pathology (Kauppila, European Journal of Vascular and Endovascular Surgery, 2009). Endplate calcification and sclerosis block nutrient transport from blood supply to the disc, and endplate marrow contact channel occlusions correlate with disc degeneration severity (Benneker et al., Spine, 2005). Endothelial dysfunction — impairment of the blood vessel lining that regulates blood flow and nutrient exchange — compromises this already limited vascular supply, reducing the disc’s access to oxygen, glucose, and amino acids while impairing removal of metabolic waste products. Insulin resistance, chronic inflammation, and smoking all promote endothelial dysfunction, connecting the vascular domain to the metabolic and inflammatory domains through shared endothelial pathology.

4.7 Structural Integrity and Repair

Disc herniation, facet arthropathy, ligamentum flavum hypertrophy, and spinal stenosis are the structural findings that drive conventional treatment decisions. These findings are real and clinically important. However, the near-universal prevalence of disc degeneration in asymptomatic populations (37% at age 20, 96% at age 80; Brinjikji et al., AJNR, 2015) demonstrates that structural degeneration alone is insufficient to explain who develops pain and who does not. The structural domain in cellular systems theory represents the visible downstream consequence of upstream dysfunction across the metabolic, inflammatory, hormonal, vascular, and mitochondrial domains operating over years or decades.

5. Inter-Domain Cascade Mechanics

5.1 The Metabolic-Inflammatory-Structural Cascade

Insulin resistance (Que et al., 2025) promotes chronic hyperglycemia, generating AGEs that cross-link disc collagen and impair nutrient diffusion. Simultaneously, insulin resistance activates NF-κB (Niederberger and Geisslinger, 2008), upregulating MMPs that degrade the disc matrix (Risbud and Shapiro, 2014). Visceral adipose tissue produces TNF-α and IL- 6, which reach the disc through its limited vascular supply. Endothelial dysfunction from insulin resistance further compromises vertebral endplate perfusion. The result is progressive disc degeneration driven not by mechanical load but by metabolic environment. An epidural steroid injection can temporarily suppress the inflammatory component at the nerve root, but it cannot reverse the AGE accumulation, the MMP activation, the endothelial dysfunction, or the adipose-derived cytokine production. This explains why many patients experience temporary relief followed by recurrence: the structural-mechanical intervention addresses the symptom without modifying the biology.

5.2 The Pain-Deconditioning-Metabolic Cascade

Chronic low back pain reduces physical activity. Skeletal muscle is the primary tissue for glucose disposal, and reduced physical activity worsens insulin resistance. Deconditioning reduces mitochondrial density in muscle tissue, further impairing metabolic flexibility. Reduced exercise eliminates the anti-inflammatory effects of physical activity, including endogenous MOTS-c production (which increases approximately 12-fold in skeletal muscle during exercise; Lee et al., Cell Metabolism, 2015). The pain itself worsens insulin resistance through the bidirectional pain-insulin resistance relationship (Zhai et al., 2016). Opioid treatment for this pain promotes further deconditioning, suppresses the HPA axis, reduces testosterone, disrupts sleep architecture, and causes weight gain — actively accelerating the metabolic cascade while modulating pain perception.

5.3 The Sleep-Hormone-Repair Cascade

Sleep disruption (Finan et al., 2013; Choy, 2015) reduces deep sleep- dependent growth hormone release, impairing disc repair and collagen maintenance. HPA axis dysregulation from chronic stress produces cortisol abnormalities that degrade connective tissue (Heim et al., 2000). Low testosterone reduces anabolic capacity for tissue repair. The structural damage from the metabolic-inflammatory cascade cannot be repaired because the hormonal environment required for repair is itself dysfunctional. Standard pharmacological sleep aids (benzodiazepines, Z- drugs) often suppress deep sleep stages rather than restoring them, potentially worsening this cascade.

5.4 The Gut-Immune-Sensitization Cascade

Gut barrier dysfunction (Camilleri, 2019) produces systemic LPS translocation and NF-κB-mediated inflammation. This systemic inflammatory tone activates spinal cord glial cells, promoting central sensitization (Watkins and Maier, 2002; Woolf, 2011). The resulting pain amplification causes a patient with moderate disc degeneration to experience severe symptoms because the nerve root is already primed by systemic inflammation. Simultaneously, gut dysbiosis reduces serotonin production, weakening descending pain inhibition. NSAIDs and opioids both produce gastrointestinal adverse effects that may worsen gut barrier function, potentially accelerating this cascade in treated patients.

6. Clinical Scenarios: Individualized Domain Assessment

The following composite clinical scenarios illustrate how cellular systems theory guides individualized assessment and intervention. All laboratory values represent plausible clinical findings consistent with the domain dysfunction documented in the cited studies.

6.1 Patient A: Metabolic-Inflammatory Dominant

Pattern Presentation: 52-year-old man, BMI 36, with 4-year history of chronic low back pain. MRI shows L4-5 broad-based disc protrusion with mild bilateral foraminal narrowing and moderate facet arthropathy at L4-5 and L5-S1. Three prior epidural steroid injections provided 3–6 weeks of relief each. Currently taking naproxen daily and hydrocodone 10mg twice daily. Pain 7/10. Unable to walk more than 15 minutes. Sleep 4–5 hours per night with frequent awakenings. Domain Assessment — Laboratory Findings: Fasting insulin 28 µIU/mL (elevated; reference <10), HbA1c 6.2% (prediabetic), HOMA-IR 6.8 (elevated; reference <2.0), triglycerides 248 mg/dL, HDL 34 mg/dL. hs-CRP 6.1 mg/L (significantly elevated systemic inflammation). Total testosterone 218 ng/dL (low; reference 300–900), free testosterone 4.2 pg/mL (low). TSH 3.8 mIU/L with low-normal free T3. Morning cortisol 4.1 µg/dL (low; reference 10–20). Vitamin D 16 ng/mL (deficient). Omega-3 index 2.9% (critically low). RBC magnesium low. Domain Interpretation: This patient’s laboratory pattern demonstrates the metabolic-inflammatory-structural cascade. Severe insulin resistance (HOMA-IR 6.8) is driving AGE accumulation, NF-κB activation, and endothelial dysfunction that accelerate disc degeneration. Markedly elevated hs-CRP confirms systemic inflammation likely driven by both insulin resistance and visceral adiposity. Low testosterone and low morning cortisol reflect neuroendocrine domain exhaustion, removing the anabolic capacity needed for tissue repair and the anti-inflammatory brake on NF-κB. Severely deficient vitamin D and omega-3 index impair anti-inflammatory pathways. His current opioid use is suppressing the HPA axis (worsening cortisol), reducing testosterone (worsening the anabolic deficit), disrupting sleep architecture (preventing growth hormone release), and causing constipation (potentially worsening gut barrier function). Each epidural injection temporarily suppressed local inflammation without modifying any of these upstream drivers. The disc is degenerating because the biological environment is destroying it. Individualized Protocol: Metabolic optimization: anti-inflammatory dietary protocol guided by continuous glucose monitoring, targeting insulin sensitization. Graded walking program progressing to Zone 2 exercise. Opioid taper with close monitoring, using interventional procedures for acute flares during taper. Testosterone optimization guided by endocrine assessment. Thyroid optimization. Vitamin D repletion to 50–80 ng/mL. Omega-3 repletion to index >8%. Magnesium repletion. MOTS-c (5–10 mg SC three times weekly, morning) targeting AMPK activation and insulin sensitization (Lee et al., Cell Metabolism, 2015). BPC-157 (250–500 µg orally twice daily) for gut barrier support during opioid taper and nitric oxide restoration (Gwyer et al., Cell and Tissue Research, 2019). GHK-Cu (1–2 mg SC daily) for collagen and GAG stimulation and gene expression modulation toward tissue repair (Pickart and Margolina, BioMed Research International, 2014). DSIP (100–200 µg SC at bedtime) for deep sleep restoration and growth hormone release. Ipamorelin/CJC-1295 (200–300 µg/100 µg SC at bedtime, five nights per week) for growth hormone secretion. SS-31 (5–10 mg SC daily) for mitochondrial membrane stabilization (Szeto, British Journal of Pharmacology, 2014). Reassessment of metabolic markers, inflammatory markers, hormonal panel, and repeat imaging at 6 months.

6.2 Patient B: Gut-Inflammatory-Sensitization

Dominant Pattern Presentation: 38-year-old woman, BMI 24, with 2-year history of low back pain following pregnancy. MRI shows mild L5-S1 disc desiccation without herniation or significant stenosis. Pain is disproportionate to imaging findings. Reports bloating, food sensitivities, and alternating bowel habits since pregnancy. Anxiety rated 6/10. Pain 6/10 with marked allodynia (pain from light touch) over the lumbar paraspinals. Previous physical therapy provided moderate improvement; gabapentin 300mg TID provided minimal benefit. Domain Assessment — Laboratory Findings: Fasting insulin 7 µIU/mL (normal), HbA1c 5.1% (normal). hs-CRP 2.8 mg/L (mildly elevated). IL-6 mildly elevated on cytokine panel. Cortisol elevated at 8PM (loss of normal diurnal decline). Positive SIBO breath test. Elevated zonulin (intestinal permeability marker). Microbiome analysis showing reduced diversity with depleted Lactobacillus and Bifidobacterium species. Vitamin D 28 ng/mL (suboptimal). B12 normal. Hormonal panel otherwise unremarkable. Domain Interpretation: This patient’s pattern demonstrates the gut- immune-sensitization cascade. Normal metabolic markers exclude insulin resistance as the primary driver. The pain disproportionate to imaging findings, combined with allodynia, suggests central sensitization (Woolf, Pain, 2011). Positive SIBO and elevated zonulin confirm gut barrier dysfunction feeding systemic inflammation through LPS translocation (Camilleri, Gut, 2019). Mildly elevated IL-6 and hs-CRP confirm the systemic inflammatory tone. Elevated evening cortisol reflects HPA axis overactivation (early phase of stress response). The gut-immune-brain cascade is driving central sensitization in a patient whose structural pathology is minimal. Gabapentin addressed calcium channel modulation (one pathway) without addressing the gut barrier dysfunction feeding the inflammation that drives the sensitization. Individualized Protocol: SIBO treatment per established protocols. Oral BPC-157 (250–500 µg twice daily) for gut barrier restoration (Gwyer et al., Cell and Tissue Research, 2019). KPV (200–400 µg orally twice daily) for NF-κB inhibition at the gut mucosal level (Niederberger and Geisslinger, FASEB Journal, 2008). Elimination dietary protocol. Probiotic repletion targeting depleted species. Selank (250–500 µg SC two to three times daily) for anxiety and HPA axis modulation without sedation or GI side effects (Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008). Vitamin D optimization. Continued physical therapy with graded exposure approach for central sensitization. Reassessment of SIBO, intestinal permeability, inflammatory markers, and cortisol curve at 12 weeks.

6.3 Patient C: Structural-Vascular-Hormonal Dominant

Pattern Presentation: 62-year-old woman, 3 years postmenopausal, with progressive low back and bilateral leg pain over 5 years. MRI shows multilevel disc degeneration L3-S1 with moderate central stenosis at L4-5, bilateral facet arthropathy, and ligamentum flavum hypertrophy. Previous L4-5 laminectomy 2 years ago provided 6 months of improvement followed by gradual return of symptoms. Now considering revision surgery. Pain 8/10. Unable to walk more than one block. Domain Assessment — Laboratory Findings: Fasting insulin 14 µIU/mL (mildly elevated), HbA1c 5.6% (upper normal). hs-CRP 3.4 mg/L (elevated). Estradiol <15 pg/mL (postmenopausal). Total testosterone 12 ng/dL (low even for postmenopausal women). DHEA-S markedly low. Vitamin D 20 ng/mL (deficient). Organic acids showing elevated methylmalonic acid (functional B12 insufficiency) and markers consistent with impaired mitochondrial function. Omega-3 index 3.1% (critically low). IGF-1 low- normal (suggesting growth hormone insufficiency). Domain Interpretation: This patient demonstrates the structural-vascular- hormonal cascade. Postmenopausal estrogen decline accelerates disc degeneration through loss of estrogen’s anti-inflammatory and disc- protective effects. Markedly low testosterone and DHEA-S remove anabolic support for connective tissue maintenance. Low IGF-1 suggests growth hormone insufficiency, impaired tissue repair. Mild insulin resistance and elevated hs-CRP confirm metabolic-inflammatory contribution. Functional B12 insufficiency impairs methylation and myelin maintenance. Her prior laminectomy corrected the structural stenosis but did not address the hormonal depletion, metabolic dysfunction, or inflammatory environment driving multilevel degeneration. Adjacent segment disease following surgery is the expected outcome when the biological environment producing degeneration remains active. Individualized Protocol: Hormonal optimization: estradiol, testosterone, and DHEA replacement guided by endocrine assessment. Vitamin D repletion. B12 repletion (methylcobalamin form). Omega-3 repletion. Anti- inflammatory dietary protocol. MOTS-c (5–10 mg SC three times weekly) for metabolic optimization (Lee et al., Cell Metabolism, 2015). GHK-Cu (1–2 mg SC daily) for collagen/GAG stimulation and gene expression reset (Pickart and Margolina, 2014; Pickart et al., 2018). TB-500 (750 µg to 1.5 mg SC twice weekly) for tissue remodeling with anti-fibrotic properties (Malinda et al., Journal of Investigative Dermatology, 1999). Ipamorelin/CJC-1295 at bedtime for growth hormone restoration. NAD+ (IV 250–500 mg 1–2x weekly for loading) for mitochondrial energy substrate. Glutathione (IV 600–1200 mg 1–2x weekly) for antioxidant defense. Interventional management (nerve blocks, RFA) for symptomatic control during biological optimization. Defer revision surgery pending 6-month reassessment of biological markers and symptoms.

7. Emerging Peptide Therapeutics: Domain-Targeted Intervention

Peptide therapeutics offer the potential for domain-targeted intervention in low back pain. Unlike single-mechanism pharmaceuticals, peptides interact with biological signaling pathways that may address domain-level dysfunction. The following peptides have published evidence connecting their mechanisms to biological domains documented as dysfunctional in low back pain. No randomized controlled trials of these peptides in low back pain populations have been published; evidence is extrapolated from mechanism-of-action studies and trials in related conditions. MOTS-c activates AMPK to improve insulin sensitivity, reduce inflammatory cytokines, and promote metabolic homeostasis (Lee et al., Cell Metabolism, 2015). Targets the insulin resistance documented as independently associated with low back pain (Que et al., 2025). SC 5–10 mg three times weekly, morning. Not FDA-approved. BPC-157 restores gut barrier integrity, reduces intestinal inflammation, restores nitric oxide production, and has demonstrated nerve regeneration in sciatic nerve transection models with faster axonal regeneration, improved myelination, and functional recovery (Gjurasin et al., Regulatory Peptides, 2010; Perovic et al., Journal of Orthopaedic Surgery and Research, 2019; Gwyer et al., Cell and Tissue Research, 2019). Oral 250– 500 µg twice daily. Not FDA-approved. GHK-Cu stimulates collagen, elastin, and glycosaminoglycan production, promotes nerve outgrowth, and modulates approximately 32% of human gene expression toward repair patterns (Pickart and Margolina, BioMed Research International, 2014; Pickart et al., International Journal of Molecular Sciences, 2018). Directly targets the structural proteins of the disc matrix. SC 1–2 mg daily. Not FDA-approved. TB-500 promotes cell migration to injured tissue and anti-fibrotic tissue remodeling (Malinda et al., Journal of Investigative Dermatology, 1999). SC 750 µg–1.5 mg twice weekly. Not FDA-approved. SS-31 (elamipretide) stabilizes the inner mitochondrial membrane by binding cardiolipin, improving electron transport chain efficiency and ATP production (Szeto, British Journal of Pharmacology, 2014; Birk et al., JASN, 2013; Karaa et al., Neurology, 2018). SC 5–10 mg daily. Not FDA-approved for pain. KPV directly inhibits NF-κB without immune suppression, concentrating in gastrointestinal mucosa. Targets the inflammatory amplification pathway. Oral 200–400 µg twice daily. Not FDA-approved. DSIP promotes delta-wave deep sleep architecture for growth hormone release and tissue repair. SC 100–200 µg at bedtime. Not combined with benzodiazepines. Not FDA-approved. Selank modulates GABA for anxiolysis without sedation; anxiolytic effect comparable to benzodiazepine in 62-patient GAD study (Zozulia et al., 2008). SC 250–500 µg 2–3x daily. Not FDA-approved in US. NAD+ and Glutathione provide cellular energy substrate and master antioxidant defense respectively. NAD+ by IV 250–500 mg 1–2x weekly. Glutathione by IV 600–1200 mg 1–2x weekly. Neither FDA-approved as therapeutic agents. Ipamorelin/CJC-1295 stimulate pulsatile growth hormone release for tissue repair and connective tissue maintenance. SC at bedtime, 5 nights/week. Temporally separated from MOTS-c by ≥8 hours. Not FDA- approved. Peptide selection is directed by laboratory findings and domain assessment, not applied as a standardized protocol. The clinical scenarios in Section 6 illustrate this principle. Because peptides operate across multiple biological pathways, additional peptides targeting immune regulation, detoxification, and other domains may be indicated based on individual assessment.

8. Discussion

The evidence reviewed in this paper supports three propositions. First, chronic low back pain involves measurable dysfunction across multiple biological domains, not merely structural pathology at a single spinal segment. Insulin resistance, systemic inflammation, hormonal insufficiency, gut barrier dysfunction, oxidative stress, endothelial dysfunction, and structural degeneration have each been independently documented in association with low back pain through peer-reviewed research. Second, the limited, partial, short-term response to single-pathway treatments is consistent with a multi-domain disorder. When 1 in 10 non- surgical treatments is efficacious with small effect sizes (Cashin et al., 2025), when opioids have an NNT of 19 (Petzke et al., 2015), and when epidural injections show short-term but not long-term benefit (AAN, 2025; Bicket et al., 2013), the data are not showing that these interventions are useless — they are showing that these interventions address only one component of a multi-component problem. The near-universal prevalence of disc degeneration in asymptomatic populations (Brinjikji et al., 2015) further demonstrates that structural pathology alone cannot explain who develops pain. Third, conventional treatments can actively worsen domains they do not target. Opioids suppress the HPA axis, reduce testosterone, disrupt sleep, cause weight gain, and impair gut function — actively accelerating the metabolic-inflammatory cascade while modulating pain perception. NSAIDs and opioids both produce gastrointestinal effects that may worsen gut barrier function. Epidural steroids may suppress local immune function at the injection site. These destabilizing effects help explain why chronic low back pain is often a progressive condition despite ongoing treatment. Cellular systems theory does not dismiss structural-mechanical diagnosis or treatment. Structural findings are real and interventional procedures provide essential acute relief. The theory proposes that structural findings represent the visible consequence of upstream biological dysfunction, and that durable improvement requires addressing both the structural damage and the biological environment that produced it. The clinical question shifts from “which structure is damaged?” to “which biological domains created the conditions for this structure to fail, and how can they be corrected?” Limitations include the narrative methodology, the observational and cross- sectional nature of key metabolic studies, the preclinical basis of most peptide evidence, and the absence of randomized controlled trials testing multi-domain interventions in low back pain populations. The clinical scenarios are composite illustrations, not case reports from controlled studies. Prospective trials comparing individualized domain-targeted protocols with standard care are needed.

9. Conclusion

Chronic low back pain is treated as a structural-mechanical disorder amenable to structural-mechanical intervention, yet the published evidence demonstrates multi-domain biological dysfunction and limited single- pathway treatment efficacy. Cellular systems theory provides a framework for understanding why the disc degenerates, why the nerve root becomes symptomatic, and why conventional treatments provide temporary or partial relief. By identifying and addressing the metabolic, inflammatory, hormonal, microbiome, mitochondrial, and vascular domains driving the condition in each individual patient, cellular systems analysis offers a path toward more durable outcomes. Emerging peptide therapeutics targeting these domains warrant prospective clinical investigation in low back pain populations.

Author Information

Ty Thomas, MD, is CEO and Medical Director of Alabama Pain Physicians, a board-certified interventional pain practice in Birmingham and Bessemer, Alabama. Dr. Thomas is board-certified in Physical Medicine and Rehabilitation with additional certification in Venous and Lymphatic Medicine. Alabama Pain Physicians integrates functional laboratory assessment and metabolic optimization with conventional pain management. Contact: 205.332.3160. BamaPain.com. Disclosures: The author reports no external conflicts of interest relevant to this manuscript. Alabama Pain Physicians offers the laboratory panels and peptide therapeutics described in this review as clinical services. No external funding was received for this work.

References

1. GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of lowback pain, 1990–2020. Lancet Rheumatology. 2023;5(6):e316-e329.

2. Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and healthcondition, 1996–2016. JAMA. 2020;323(9):863-884.

3. Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need topay attention. Lancet. 2018;391(10137):2356-2367.

4. Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain.Lancet. 2018;391(10137):2368-2383.

5. Cashin AG, Furlong BM, Kamper SJ, et al. Analgesic effects of non-surgical treatmentsfor low back pain: systematic review and meta-analysis. BMJ Evidence Based Medicine. 2025;bmjebm-2024-112974.

6. Petzke F, Welsch P, Klose P, et al. Opioids in chronic low back pain: systematic reviewand meta-analysis. Schmerz. 2015;29(1):60-72.

7. Martell BA, O’Connor PG, Kerns RD, et al. Systematic review: opioid treatment forchronic back pain. Annals of Internal Medicine. 2007;146(2):116-127.

8. AAN Guidelines Subcommittee. Epidural steroids for radicular pain and spinal stenosis:systematic review summary. Neurology. 2025;104(6):e210258.

9. Bicket MC, Gupta A, Brown CH, Cohen SP. Epidural injections for spinal pain: meta-analysis. Anesthesiology. 2013;119(4):907-931.

10. Kuijpers T, van Middelkoop M, Rubinstein SM, et al. Effectiveness of pharmacologicalinterventions for chronic non-specific low-back pain. European Spine Journal. 2011;20(1):40-50.

11. Brinjikji W, Luetmer PH, Comstock B, et al. Systematic review of imaging features ofspinal degeneration in asymptomatic populations. AJNR. 2015;36(4):811-816.

12. Que Z, Chen D, Cai H, et al. Insulin resistance and low back pain in US adults.Frontiers in Medicine. 2025;12:1538754.

13. Guo W, Li BL, Zhao JY, et al. Causal associations between modifiable risk factors andintervertebral disc degeneration. Spine Journal. 2024;24(2):195-209.

14. Teraguchi M, Yoshimura N, Hashizume H, et al. Metabolic syndrome components andintervertebral disc degeneration: the Wakayama Spine Study. PLoS One. 2016;11(2):e0147565.

15. Zhai X, Sun C, Rong P, et al. Chronic pain and insulin resistance. Journal of Pain.2016;17:404-413.

16. Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration. NatureReviews Rheumatology. 2014;10(1):44-56.

17. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus inducesneurophysiologic and histologic changes in cauda equina nerve roots. Spine. 1993;18(11):1425-1432.

18. Niederberger E, Geisslinger G. The IKK-NF-κB pathway. FASEB Journal.2008;22(10):3432-3442.

19. Watkins LR, Maier SF. Immune and glial cells in pathological pain. PhysiologicalReviews. 2002;82(4):981-1011.

20. Woolf CJ. Central sensitization. Pain. 2011;152(3 Suppl):S2-S15.

21. Finan PH, Goodin BR, Smith MT. Sleep and pain association. Journal of Pain.2013;14(12):1539-1552.

22. Choy EH. Sleep in pain and fibromyalgia. Nature Reviews Rheumatology.2015;11(9):513-520.

23. Heim C, Ehlert U, Hellhammer DH. Hypocortisolism in stress-related disorders.Psychoneuroendocrinology. 2000;25(1):1-35.

24. Camilleri M. Leaky gut: mechanisms and implications. Gut. 2019;68(8):1516-1526.

25. Minerbi A, et al. Altered microbiome in fibromyalgia. Pain. 2019;160(11):2589-2602.

26. Erdrich S, et al. Fibromyalgia and SIBO. Clinical and Experimental Rheumatology.2020;38(Suppl 123):165-175.

27. Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metabolism.2015;21(3):443-454.

28. Gjurasin M, et al. BPC 157 in traumatic nerve injury. Regulatory Peptides. 2010;160(1-3):33-41.

29. Perovic D, et al. BPC 157 in spinal cord injury. Journal of Orthopaedic Surgery andResearch. 2019;14(1):199.

30. Gwyer D, et al. BPC 157 in musculoskeletal healing. Cell and Tissue Research.2019;377(2):153-159.

31. Pickart L, Margolina A. GHK and DNA: resetting the genome. BioMed ResearchInternational. 2014;2014:151479.

32. Pickart L, et al. GHK-Cu regenerative actions. International Journal of MolecularSciences. 2018;19(7):1987.

33. Malinda KM, et al. Thymosin beta4 in wound healing. Journal of InvestigativeDermatology. 1999;113(3):364-368.

34. Szeto HH. Cardiolipin-protective compound for mitochondrial bioenergetics. BritishJournal of Pharmacology. 2014;171(8):2029-2050.

35. Birk AV, et al. SS-31 re-energizes mitochondria via cardiolipin. JASN. 2013;24(8):1250-

1261.

36. Karaa A, et al. Elamipretide trial in mitochondrial myopathy. Neurology.2018;90(14):e1212-e1221.

37. Zozulia AA, et al. Selank in generalized anxiety. Zh Nevrol Psikhiatr. 2008;108(4):38-

48.

38. Helde-Frankling M, Björkhem-Bergman L. Vitamin D in pain management. IJMS.2017;18(10):2170.

39. Li Y, Chen L, Gao Y, Zou X, Wei F. Oxidative stress and intervertebral discdegeneration: pathophysiology, signaling pathway, and therapy. Oxidative Medicine and Cellular Longevity. 2022;2022:1984742.

40. Wang Y, Cheng H, Wang T, Zhang K, Zhang Y, Kang X. Oxidative stress inintervertebral disc degeneration: molecular mechanisms, pathogenesis and treatment. Cell Proliferation. 2023;56(9):e13448.

41. Suzuki S, et al. Excessive reactive oxygen species are therapeutic targets forintervertebral disc degeneration. Spine. 2015;40(15):E894-E902.

42. Cheng X, et al. The Nrf2 antioxidant defense system in intervertebral discdegeneration: molecular insights. Experimental and Molecular Medicine. 2022;54:1619-1630.

43. Urban JP, Smith S, Fairbank JC. Nutrition of the intervertebral disc. Spine.2004;29(23):2700-2709.

44. Kauppila LI. Atherosclerosis and disc degeneration/low-back pain — a systematicreview. European Journal of Vascular and Endovascular Surgery. 2009;37(6):661-670.

45. Benneker LM, Heini PF, Alini M, Anderson SE. 2004 Young Investigator AwardWinner: vertebral endplate marrow contact channel occlusions and intervertebral disc degeneration. Spine. 2005;30(2):167-173.

© 2026 Alabama Pain Physicians. All rights reserved.